The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Viridian Reports Positive Phase 1 Results for VRDN008
Research & Innovations Latest News

Viridian Reports Positive Phase 1 Results for VRDN-008

Investigational therapy demonstrates sustained IgG reductions for up to eight weeks, supporting less frequent dosing for autoimmune diseases

11/18/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Clinical Scorecard: Viridian Reports Positive Phase 1 Results for VRDN-008

At a Glance

CategoryDetail
ConditionAutoantibody-mediated autoimmune diseases; VRDN-008 is investigational and has not demonstrated clinical benefit in any disease.
Key MechanismsVRDN-008 is a half-life-extended neonatal Fc receptor inhibitor designed to reduce circulating IgG antibodies.
Target PopulationPhase 1 participants were healthy volunteers; planned clinical development includes patients with myasthenia gravis.
Care SettingEarly-phase clinical research; no disease-specific clinical use is established.

Key Highlights

  • In a Phase 1 study in healthy volunteers, VRDN-008 produced a peak IgG reduction of 74%, with suppression maintained for up to eight weeks after administration.
  • The reported drug half-life was 15–18 days, approximately six times longer than first-generation Fc fragments.
  • Participants received two subcutaneous doses, at baseline and week four.
  • The therapy was generally well tolerated; no serious adverse events or dose-limiting toxicities were reported, and albumin and LDL cholesterol were not reduced.
  • Viridian plans to begin at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027, subject to regulatory feedback.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • The source reports no serious adverse events or dose-limiting toxicities in the Phase 1 study; it does not provide further safety details.
        • VRDN-008 has not demonstrated clinical benefit in thyroid eye disease, and no TED-specific development program has been announced.

        Patient & Prescribing Data

        The Phase 1 study evaluated subcutaneous VRDN-008 in healthy volunteers. Planned pivotal development is expected to begin with myasthenia gravis; no patient-use indication is established.

        Participants received doses at baseline and week four. The company plans to evaluate dosing every four and eight weeks in a proposed placebo-controlled study. VRDN-008 remains investigational.

        Clinical Best Practices

        • Interpret the reported IgG reductions and safety findings as Phase 1 results in healthy volunteers, not evidence of clinical efficacy in patients.
        • Do not infer a role for VRDN-008 in thyroid eye disease: the source reports no demonstrated TED benefit or TED-specific development program.
        • Further clinical trials are needed to determine whether prolonged IgG suppression translates into meaningful patient outcomes.

        Related Resources & Content

        • Viridian Therapeutics announcement, as summarized in the supplied article

        This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

        Related Content

        Newsletters

        Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

        Newsletter Signup Image

        False

        Advertisement

        False

        Advertisement

        Explore More in Ophthalmology

        Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

        False

        Advertisement
        The Ophthalmologist
        Subscribe

        About

        • About Us
        • Work at Conexiant Europe
        • Terms and Conditions
        • Privacy Policy
        • Your Privacy Choices
        • Advertise With Us
        • Contact Us

        Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

        Affiliations:

        Specialties:

        Areas of Expertise:

        Contributions:

        Disclaimer

        The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: